Unknown

Dataset Information

0

The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase.


ABSTRACT: Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme that is implicated in suppressing T-cell immunity in many settings including cancer. In recent years, we have described spontaneous CD8(+) as well as CD4(+) T-cell reactivity against IDO in the tumor microenvironment of different cancer patients as well as in the peripheral blood of both cancer patients and to a lesser extent in healthy donors. We have demonstrated that IDO-reactive CD8(+) T cells were peptide-specific, cytotoxic effector cells, which are able to recognize and kill IDO-expressing cells including tumor cells as well as dendritic cells. Consequently, IDO may serve as a widely applicable target for immunotherapeutic strategies with a completely different function as well as expression pattern compared to previously described antigens. IDO constitutes a significant counter-regulatory mechanism induced by pro-inflammatory signals, and IDO-based immunotherapy may consequently be synergistic with additional immunotherapy. In this regard, we have shown that the presence of IDO-specific T cells boosted immunity against CMV and tumor antigens by eliminating IDO(+) suppressive cells and changing the regulatory microenvironment. The current review summarizes current knowledge of IDO as a T-cell antigen, reports the initial results that are suggesting a general function of IDO-specific T cells in immunoregulation, and discusses future opportunities.

SUBMITTER: Andersen MH 

PROVIDER: S-EPMC3401509 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase.

Andersen Mads Hald MH  

Cancer immunology, immunotherapy : CII 20120303 8


Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme that is implicated in suppressing T-cell immunity in many settings including cancer. In recent years, we have described spontaneous CD8(+) as well as CD4(+) T-cell reactivity against IDO in the tumor microenvironment of different cancer patients as well as in the peripheral blood of both cancer patients and to a lesser extent in healthy donors. We have demonstrated that IDO-reactive CD8(+) T cells were peptide-specific, cytotoxic ef  ...[more]

Similar Datasets

| S-EPMC3335144 | biostudies-literature
| S-EPMC3062329 | biostudies-literature
| S-EPMC4678703 | biostudies-literature
| S-EPMC3733714 | biostudies-literature
| S-EPMC3645912 | biostudies-literature
| S-EPMC5879690 | biostudies-literature
| S-EPMC4368142 | biostudies-literature
| S-EPMC6828782 | biostudies-literature
| S-EPMC3938761 | biostudies-literature
| S-EPMC7765568 | biostudies-literature